Takeda has bought a licence for a coeliac disease drug from COUR Pharmaceuticals, after the US biotech announced supportive phase 2a trial data. Gastrointestinal diseases are one of the Japanese ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results